Matthew Fenech

Dr. Matthew Fenech

Una Health GmbH, Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2014 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MRMeritxell Rosell
Meritxell Rosell
MKMyrsini Kaforou
Myrsini Kaforou
Andrea FrontiniAndrea Frontini
Andrea Frontini
AOAnthony Okolo
Anthony Okolo
YCYi-Wah Chan
Yi-Wah Chan
Mark ChristianMark Christian
Mark Christian
Brown adipocytes dissipate energy, whereas white adipocytes are an energy storage site. We explored the plasticity of different white adipose tissue depots in acquiring a brown phenotype by cold exposure. By comparing cold-induced genes in white fat to those enriched in brown compared with white fat, at thermoneutrality we defined a “brite” transcription signature. We identified the genes, pathways, and promoter regulatory motifs associated with “browning,” as these represent novel targets for understanding this process. For example, neuregulin 4 was more highly expressed in brown adipose tissue and upregulated in white fat upon cold exposure, and cell studies showed that it is a neurite outgrowth-promoting adipokine, indicative of a role in increasing adipose tissue innervation in response to cold. A cell culture system that allows us to reproduce the differential properties of the discrete adipose depots was developed to study depot-specific differences at an in vitro level. The key transcriptional events underpinning white adipose tissue to brown transition are important, as they represent an attractive proposition to overcome the detrimental effects associated with metabolic disorders, including obesity and type 2 diabetes.

9 March 2017 in Blood
Verified
Journal Article
Closed access
PDF file
MSManar S. Shafat
Manar S. Shafat
TOThomas Oellerich
Thomas Oellerich
SMSebastian Mohr
Sebastian Mohr
SRStephen D. Robinson
Stephen D. Robinson
DEDylan R. Edwards
Dylan R. Edwards
SRStuart Rushworth
Stuart Rushworth
Key Points: Bone marrow adipocytes support AML survival. AML induces adipocyte lipolysis of triglyceride to free fatty acids and subsequent transport by FABP4.

26 September 2014 in Science
Verified
Journal Article
Closed access
PDF file
LCLu Chen
Lu Chen
MKMyrto Kostadima
Myrto Kostadima
JMJ. H. A. Martens
J. H. A. Martens
Giovanni CanuGiovanni Canu
Giovanni Canu
SGSara P. Garcia
Sara P. Garcia
ARAugusto Rendon
Augusto Rendon
A BLUEPRINT of immune cell development: To determine the epigenetic mechanisms that direct blood cells to develop into the many components of our immune system, the BLUEPRINT consortium examined the regulation of DNA and RNA transcription to dissect the molecular traits that govern blood cell differentiation. By inducing immune responses, Saeed et al. document the epigenetic changes in the genome that underlie immune cell differentiation. Cheng et al. demonstrate that trained monocytes are highly dependent on the breakdown of sugars in the presence of oxygen, which allows cells to produce the energy needed to mount an immune response. Chen et al. examine RNA transcripts and find that specific cell lineages use RNA transcripts of different length and composition (isoforms) to form proteins. Together, the studies reveal how epigenetic effects can drive the development of blood cells involved in the immune system. Science , this issue 10.1126/science.1251086 , 10.1126/science.1250684 , 10.1126/science.1251033

26 October 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SGStephen Gilbert
Stephen Gilbert
MFMatthew Fenech
Matthew Fenech
MHMartin C. Hirsch
Martin C. Hirsch
SUShubhanan Upadhyay
Shubhanan Upadhyay
ABAndrea Biasiucci
Andrea Biasiucci
JSJohannes Starlinger
Johannes Starlinger
One of the greatest strengths of artificial intelligence (AI) and machine learning (ML) approaches in health care is that their performance can be continually improved based on updates from automated learning from data. However, health care ML models are currently essentially regulated under provisions that were developed for an earlier age of slowly updated medical devices—requiring major documentation reshape and revalidation with every major update of the model generated by the ML algorithm. This creates minor problems for models that will be retrained and updated only occasionally, but major problems for models that will learn from data in real time or near real time. Regulators have announced action plans for fundamental changes in regulatory approaches. In this Viewpoint, we examine the current regulatory frameworks and developments in this domain. The status quo and recent developments are reviewed, and we argue that these innovative approaches to health care need matching innovative approaches to regulation and that these approaches will bring benefits for patients. International perspectives from the World Health Organization, and the Food and Drug Administration’s proposed approach, based around oversight of tool developers’ quality management systems and defined algorithm change protocols, offer a much-needed paradigm shift, and strive for a balanced approach to enabling rapid improvements in health care through AI innovation while simultaneously ensuring patient safety. The draft European Union (EU) regulatory framework indicates similar approaches, but no detail has yet been provided on how algorithm change protocols will be implemented in the EU. We argue that detail must be provided, and we describe how this could be done in a manner that would allow the full benefits of AI/ML-based innovation for EU patients and health care systems to be realized.

31 August 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AHAdam Hulman
Adam Hulman
ODOle Lindgård Dollerup
Ole Lindgård Dollerup
JMJesper Friis Mortensen
Jesper Friis Mortensen
MFMatthew Fenech
Matthew Fenech
KNKasper Norman
Kasper Norman
THTroels Krarup Hansen
Troels Krarup Hansen
Large language models have received enormous attention recently with some studies demonstrating their potential clinical value, despite not being trained specifically for this domain. We aimed to investigate whether ChatGPT, a language model optimized for dialogue, can answer frequently asked questions about diabetes. We conducted a closed e-survey among employees of a large Danish diabetes center. The study design was inspired by the Turing test and non-inferiority trials. Our survey included ten questions with two answers each. One of these was written by a human expert, while the other was generated by ChatGPT. Participants had the task to identify the ChatGPT-generated answer. Data was analyzed at the question-level using logistic regression with robust variance estimation with clustering at participant level. In secondary analyses, we investigated the effect of participant characteristics on the outcome. A 55% non-inferiority margin was pre-defined based on precision simulations and had been published as part of the study protocol before data collection began. Among 311 invited individuals, 183 participated in the survey (59% response rate). 64% had heard of ChatGPT before, and 19% had tried it. Overall, participants could identify ChatGPT-generated answers 59.5% (95% CI: 57.0, 62.0) of the time, which was outside of the non-inferiority zone. Among participant characteristics, previous ChatGPT use had the strongest association with the outcome (odds ratio: 1.52 (1.16, 2.00), p = 0.003). Previous users answered 67.4% (61.7, 72.7) of the questions correctly, versus non-users’ 57.6% (54.9, 60.3). Participants could distinguish between ChatGPT-generated and human-written answers somewhat better than flipping a fair coin, which was against our initial hypothesis. Rigorously planned studies are needed to elucidate the risks and benefits of integrating such technologies in routine clinical practice.

1 December 2009 in Circulation
Verified
Journal Article
Closed access
PDF file
MCMarcus P. Corander
Marcus P. Corander
MFMatthew Fenech
Matthew Fenech
ACAnthony P. Coll
Anthony P. Coll